skip
net ir
Japanese

Takeda Pharmaceutical Company Limited

code | 4502Market | TYO1, OSA1, NGO1, Fukuoka, SapCategory of Business | Pharmaceuticals
Inquiry : 12-10, Nihonbashi 2-chome, Chuo-ku, Tokyo 103-8668 [Official Homepage]
TEL :


Corporate Presentation

2019/05/15
Earnings Conference for the Financial Results for Fiscal Year 2018 (part 2)
President and Chief Executive Officer Christophe Weber
President, Research & Development Andrew Plump
Chief Financial OfficerCosta Saroukos
Global Head of Investor Relations; and others Takashi Okubo
Presentation material(PDF:4038KB)
300k
2019/05/15
Earnings Conference for the Financial Results for Fiscal Year 2018(part 1)
President and Chief Executive Officer Christophe Weber
President, Research & Development Andrew Plump
Chief Financial OfficerCosta Saroukos
Global Head of Investor Relations; and others Takashi Okubo
Presentation material(PDF:4038KB)
300k
2019/02/02
Conference Call for the Announcement of 3rd Quarter Financial Results for Fiscal Year 2018 (Part 1)
President and Chief Executive Officer Christophe Weber
Chief Financial Officer Costa Saroukos
Global Head of Investor Relations Takashi Okubo
Presentation material(PDF:733KB)
300k
2019/02/02
Conference Call for the Announcement of 3rd Quarter Financial Results for Fiscal Year 2018 (Part 2)
Chief Financial Officer Costa Saroukos
Global Head of Investor Relations Takashi Okubo
Presentation material(PDF:733KB)
300k
2019/01/10
Meeting regarding Acquisition of Shire plc by Takeda
President and Chief Executive Officer Christophe Weber
Chief Financial Officer Costa Saroukos
President of Japan Pharma Business Unit Masato Iwasaki
Global Head of Investor Relations Takashi Okubo
Presentation material(PDF:3912KB)
300k
2018/11/01
Earnings Conference for the 2nd Quarter of Fiscal Year 2018
President and Chief Executive Officer Christophe Weber
President, Japan Pharma Business Unit Masato Iwasaki
Chief Medical & Scientific Officer Andrew Plump
Chief Financial Officer Costa Saroukos
Global Head of Investor Relations Takashi Okubo
300k
2018/10/12
TAKEDA R&D INVESTOR DAY 2018
Christophe Weber
President and Chief Executive Officer

ANDY PLUMP MD, PHD
Chief Medical and Scientific Officer
PHILIP ROWLANDS, PHD
Head, Oncology Therapeutic Area
ASIT PARIKH MD, PHD
Head, Gastrointestinal Therapeutic Area
EMILIANGELO RATTI, PHD
Head, Neuroscience Therapeutic Area
CHOO BENG GOH, MD
Regional Lead for Medical Affairs Asia,
Global Vaccine Business Unit
TOSHIO FUJIMOTO, MD, MBA
General Manager, Shonan Health Innovation Park
300k
2018/07/31
Conference Call for the Announcement of 1st Quarter Financial Results for Fiscal Year 2018
President and Chief Executive Officer Christophe Weber
Chief Financial Officer Costa Saroukos
Head, R&D Integration Chris Morabito
Global Head of Investor Relations Takashi Okubo
Presentation material(PDF:408KB)
300k
2018/05/15
Conference for the Announcement of "Financial Results for Fiscal Year 2017"
President and Chief Executive Officer
Christophe Weber

Chief Medical & Scientific Officer
Andrew Plump
Chief Financial Officer
Costa Saroukos
President, Japan Pharma Business Unit
Masato Iwasaki
Global Head of Investor Relations
Takashi Okubo
Presentation material(PDF:790KB)
300k
2018/05/10
Takeda to Acquire Shire-Accelerating Takeda's Transformation to Deliver More for Patients
Christophe Weber President and CEO
Costa Saroukos Chief Financial Officer
MC:Takashi Okubo Global Head of Investor Relations
Presentation material(PDF:569KB)
300k
2018/05/09
Takeda to Acquire Shire-Accelerating Takeda's Transformation to Deliver More for Patients
President and CEO
Christophe Weber

Chief Financial Officer
Costa Saroukos
Global Head of Investor Relations
MC:Takashi Okubo
Presentation material(PDF:569KB)
300k




Precautions in use
Nomura IR assumes no responsibility for correctness, validity or any other nature of the contents on this server.
No act such as alteration, modification or addition to the contents is permitted.
Since the contents on this server are not intended to solicit investment, our company has no liability for any trouble related to investment made by any audience based on the contents of this site. Investors are required to decide at their own discretion.
Nomura IR assumes no responsibility for correctness, validity or any other nature of information, including its format and details, obtained from any site linked from our site.

up
Download Plug-in
Get Adobe Reader
Windows Media Player
Real Player
Copyright (c) 2004 Nomura Investor Relations Co., Ltd. All Rights Reserved.
NIR